Oramed Pharmaceuticals Inc. (ORMP)
ORMP Stock Price Chart
Explore Oramed Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze ORMP price movements and trends.
ORMP Company Profile
Discover essential business fundamentals and corporate details for Oramed Pharmaceuticals Inc. (ORMP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 May 2007
Employees
13.00
Website
https://www.oramed.comCEO
Nadav Kidron
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
ORMP Financial Timeline
Browse a chronological timeline of Oramed Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.04.
Earnings released on 14 Aug 2025
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%.
Earnings released on 15 May 2025
EPS came in at -$0.19 falling short of the estimated -$0.03 by -533.33%, while revenue for the quarter reached $2.00M .
Earnings released on 27 Mar 2025
EPS came in at $0.01 surpassing the estimated -$0.03 by +133.33%.
Earnings released on 7 Nov 2024
EPS came in at -$0.48 falling short of the estimated -$0.00 by -9.70K%.
Earnings released on 14 Aug 2024
EPS came in at $0.26 surpassing the estimated $0.01 by +2.50K%.
Earnings released on 9 May 2024
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%.
Earnings released on 6 Mar 2024
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%.
Earnings released on 9 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 10 Aug 2023
EPS came in at -$0.03 surpassing the estimated -$0.11 by +72.73%, while revenue for the quarter reached $674.00K , missing expectations by -3.71%.
Earnings released on 11 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.23 by +65.22%, while revenue for the quarter reached $666.00K , missing expectations by -3.29%.
Earnings released on 6 Mar 2023
EPS came in at -$0.22 matching the estimated -$0.22, while revenue for the quarter reached $681.00K , missing expectations by -4.22%.
Earnings released on 10 Nov 2022
EPS came in at -$0.18 surpassing the estimated -$0.26 by +30.77%, while revenue for the quarter reached $682.00K , missing expectations by -2.57%.
Earnings released on 10 Aug 2022
EPS came in at -$0.27 falling short of the estimated -$0.22 by -22.73%, while revenue for the quarter reached $674.00K , missing expectations by -3.71%.
Earnings released on 30 Mar 2022
EPS came in at -$0.27 falling short of the estimated -$0.19 by -41.85%, while revenue for the quarter reached $666.00K , missing expectations by -3.83%.
Earnings released on 11 Jan 2022
EPS came in at -$0.22 falling short of the estimated -$0.20 by -10.00%, while revenue for the quarter reached $674.00K , missing expectations by -3.71%.
Earnings released on 24 Nov 2021
EPS came in at -$0.21 falling short of the estimated -$0.10 by -110.00%, while revenue for the quarter reached $683.00K , missing expectations by -25.18%.
Earnings released on 14 Jul 2021
EPS came in at -$0.17 falling short of the estimated -$0.12 by -41.67%, while revenue for the quarter reached $681.00K , missing expectations by -29.79%.
Earnings released on 13 Apr 2021
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%, while revenue for the quarter reached $665.00K , meeting expectations.
Earnings released on 14 Jan 2021
EPS came in at -$0.23 falling short of the estimated -$0.16 by -43.75%, while revenue for the quarter reached $674.00K , beating expectations by +13.13%.
Earnings released on 24 Nov 2020
EPS came in at -$0.12 surpassing the estimated -$0.15 by +20.00%, while revenue for the quarter reached $681.00K .
ORMP Stock Performance
Access detailed ORMP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.